{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:21:34Z","timestamp":1788877294851,"version":"build-2803163510"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.canlet.2025.217513","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T17:24:32Z","timestamp":1738257872000},"page":"217513","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Phase Ib study of SCT200 combined with paclitaxel or docetaxel in patients with recurrent or metastatic head and neck squamous cell carcinoma following platinum-based chemotherapy and PD-1 antibody"],"prefix":"10.1016","volume":"613","author":[{"given":"Jinguan","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2784-6148","authenticated-orcid":false,"given":"Song","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuansong","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiyu","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nianyong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhendong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songnan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shurong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanghua","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangfang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangzhi","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlin","family":"Gai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8271-0921","authenticated-orcid":false,"given":"Xinyue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2406-0264","authenticated-orcid":false,"given":"Jiang","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1813-9815","authenticated-orcid":false,"given":"Ye","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.canlet.2025.217513_bib1","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Robert","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.canlet.2025.217513_bib2","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2006.06.7447","volume":"25","author":"Jan","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.canlet.2025.217513_bib3","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(17)30064-5","article-title":"Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial","volume":"18","author":"Denis","year":"2017","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.canlet.2025.217513_bib4","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1002\/cam4.3953","article-title":"Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME","volume":"10","author":"Thomas","year":"2021","journal-title":"Cancer Med."},{"issue":"11","key":"10.1016\/j.canlet.2025.217513_bib5","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1200\/JCO.2012.45.4272","article-title":"Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial","volume":"31","author":"Athanassios","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.canlet.2025.217513_bib6","doi-asserted-by":"crossref","first-page":"S853","DOI":"10.1016\/j.annonc.2022.07.803","article-title":"Clinical outcomes in patients with recurrent or metastatic head and neck squamous cell carcinoma after failure of platinum and nivolumab: a multicenter retrospective study","volume":"33","author":"Oka","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2025.217513_bib7","doi-asserted-by":"crossref","first-page":"S592","DOI":"10.1016\/j.annonc.2023.09.2086","article-title":"942P Response to salvage chemotherapy with paclitaxel \u00fe\/- cetuximab after progression on immune checkpoint inhibitors in platinum-refractory recurrent and\/or metastatic squamous cell carcinoma of the head and neck (R\/M SCCHN) patients (CeTax study)","volume":"34","author":"Herrera Gomez","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2025.217513_bib8","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3626","article-title":"The secret ally: immunostimulation by anticancer drugs","volume":"11","author":"Galluzzi","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2025.217513_bib9","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ctrv.2017.11.008","article-title":"Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation","volume":"63","author":"Ferris","year":"2018","journal-title":"Cancer Treat Rev."},{"issue":"6","key":"10.1016\/j.canlet.2025.217513_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103476","article-title":"A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody","volume":"9","author":"Koyama","year":"2024","journal-title":"ESMO Open"},{"issue":"25","key":"10.1016\/j.canlet.2025.217513_bib11","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1200\/JCO.23.02625","article-title":"Pembrolizumab plus carboplatin and paclitaxel as first-line therapy for recurrent\/metastatic head and neck squamous cell carcinoma (keynote-B10): a single-arm phase IV trial","volume":"42","author":"Dzienis","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.canlet.2025.217513_bib12","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1200\/JCO.1998.16.10.3362","article-title":"A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer","volume":"16","author":"Valero","year":"1998","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.canlet.2025.217513_bib13","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1075-122X.2004.21555.x","article-title":"Phase II study of weekly paclitaxel for docetaxel-resistant metastatic breast cancer in Japan","volume":"10","author":"Taguchi","year":"2004","journal-title":"Breast J."},{"issue":"1","key":"10.1016\/j.canlet.2025.217513_bib14","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1186\/s12885-022-10147-9","article-title":"Safety, pharmacokinetics and efficacy of SCT200, an anti-EGFR monoclonal antibody in patients with wild-type KRAS\/NRAS\/BRAF metastatic colorectal cancer: a phase I dose-escalation and dose-expansion study","volume":"22","author":"Wen","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canlet.2025.217513_bib15","article-title":"Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase \u2161 study","volume":"100","author":"Lin","year":"2024","journal-title":"EBioMedicine"},{"issue":"5","key":"10.1016\/j.canlet.2025.217513_bib16","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S1470-2045(15)70124-5","article-title":"Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial","volume":"16","author":"Machiels","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2025.217513_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2021.100754","article-title":"Therapeutic strategies to overcome taxane resistance in cancer","volume":"55","author":"Das","year":"2021","journal-title":"Drug Resist Updat"},{"issue":"6","key":"10.1016\/j.canlet.2025.217513_bib18","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/oxfordjournals.annonc.a058903","article-title":"Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind","volume":"5","author":"Verweij","year":"1994","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2025.217513_bib19","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejca.2019.08.026","article-title":"Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck","volume":"121","author":"Saleh","year":"2019","journal-title":"Eur. J. Cancer"},{"issue":"53","key":"10.1016\/j.canlet.2025.217513_bib20","doi-asserted-by":"crossref","first-page":"91795","DOI":"10.18632\/oncotarget.20030","article-title":"Excellent response to chemotherapy post immunotherapy","volume":"8","author":"Dwary","year":"2017","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.canlet.2025.217513_bib21","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.3390\/cancers12082299","article-title":"Prognostic biomarkers of salvage chemotherapy following nivolumab treatment for recurrent and\/or metastatic head and neck squamous cell carcinoma","volume":"12","author":"Wakasaki","year":"2020","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.canlet.2025.217513_bib22","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jtho.2017.10.011","article-title":"Increased response rates to salvage chemotherapy administered after PD-1\/PD-L1 inhibitors in patients with non-small cell lung cancer","volume":"13","author":"Song","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"6","key":"10.1016\/j.canlet.2025.217513_bib23","doi-asserted-by":"crossref","first-page":"e1018","DOI":"10.1002\/onco.13754","article-title":"Safety and efficacy of cetuximab-based salvage chemotherapy after checkpoint inhibitors in head and neck cancer","volume":"26","author":"Cabezas-Camarero","year":"2021","journal-title":"Oncol."},{"issue":"suppl","key":"10.1016\/j.canlet.2025.217513_bib24","doi-asserted-by":"crossref","first-page":"9000","DOI":"10.1200\/JCO.2017.35.15_suppl.9000","article-title":"Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS) 50% enrolled in KEYNOTE-024","volume":"35","author":"Brahmer","year":"2017","journal-title":"J. Clin. Oncol."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525000771?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525000771?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T22:58:36Z","timestamp":1760741916000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383525000771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":24,"alternative-id":["S0304383525000771"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2025.217513","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase Ib study of SCT200 combined with paclitaxel or docetaxel in patients with recurrent or metastatic head and neck squamous cell carcinoma following platinum-based chemotherapy and PD-1 antibody","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2025.217513","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"217513"}}